1. A fixing system for a skirting, said system comprising a skirting profile element and a coupling element, the skirting profile element having an arm to engage the upper surface of floor covering and configured to connect with the coupling element, the arm having a portion extending upwardly towards a wall, in use;
the coupling element comprising a first end portion that is substantially flat and adapted to be located under the floor covering, and a second end portion having a portion extending towards the floor covering, downwardly so that, in use, the downwardly extending portion of the coupling element bears against the upwardly extending portion of the arm to connect the coupling element with and on top of the arm of the skirting profile element, the coupling element being flexible and having a bent portion between the first and second end portions so that, in use, the second end portion can connect with the arm of the skirting profile element in a separable manner.
2. A fixing system as claimed in claim 1, wherein the arm of the skirting profile element and the coupling element are connectable in a snap-fit manner.
3. A fixing system as claimed in claim 1, wherein the coupling element is provided with a reinforcing web.
4. A fixing system as claimed in claim 1, wherein the bent portion of the coupling element has a flattened portion for abutting the wall.
5. A fixing system as claimed in claim 1, wherein the coupling element is provided with flexible inserts.
6. A fixing system for a skirting as claimed in claim 1, wherein the coupling element is provided with a leveling flexible element comprising an end configured to bear against a portion of the floor covering.
7. A fixing system as claimed in claim 1, wherein the arm of the skirting profile element has an upright protrusion for engaging the coupling element.
8. A fixing system as claimed in claim 1, wherein the downwardly extending portion of the second end portion of the coupling element forms a portion of a triangular recess configured to engage with an undercutting formed by the upwardly extending portion of the arm of the skirting profile element to connect the coupling element with and on top of the arm of the skirting profile element.
9. A fixing system as claimed in claim 1, wherein an end of the arm of the skirting profile element is configured to extend in a direction towards the wall.
10. A fixing system as claimed in claim 1, wherein the bent portion is configured to bear against the wall when the coupling element is connected with and on top of the arm of the skirting profile element.
11. A fixing system as claimed in claim 1, wherein the downwardly extending portion of the coupling element further comprises a first engagement surface and the upwardly extending portion of the arm of the skirting profile element further comprises a second engagement surface so that, in use, the first and second engagement surfaces are configured to engage with each other to connect the coupling element with and on top of the arm of the skirting profile element.
12. A fixing system as claimed in claim 11, wherein the first engagement surface is a lower surface on the underside of the coupling element and the second engagement surface is an upper surface on the top of the arm.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of Formula 1 or a pharmaceutically acceptable salt thereof:
wherein R1, R2, R3 and R4 are independently hydrogen or a non-hydrogen substituent selected from the group consisting of C1-12 alkyl unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C3-10 cycloalkyl, C5-12 aryl, C5-12 heteroaryl, hydroxyl, halogen and C1-4 alkoxycarbonyl; C3-10 cycloalkyl; C1-12 alkoxy; C5-12 aryl; C5-12 heteroaryl; hydroxyl; and halogen, and
the aryl and heteroaryl are unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, hydroxyl and halogen.
2. The compound of Formula 1 or a pharmaceutically acceptable salt thereof of claim 1, wherein R1, R2, R3 and R4 are independently hydrogen or a non-hydrogen substituent selected from the group consisting of unsubstituted C1-7 alkyl; C1-6 alkyl substituted with at least one non-hydrogen substituent selected from the group consisting of unsubstituted C3-7 cycloalkyl, C5-12 aryl, C5-12 heteroaryl, hydroxyl, halogen and C1-4 alkoxycarbonyl; unsubstituted C3-7 cycloalkyl; C1-6 alkoxy; C5-12 aryl; C5-12 heteroaryl; hydroxyl; and halogen, and
the aryl and heteroaryl are unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, hydroxyl and halogen.
3. The compound of Formula 1 or a pharmaceutically acceptable salt thereof of claim 2, wherein R1 and R4 are independently non-hydrogen substituents selected from the group consisting of unsubstituted C1-7 alkyl; C1-6 alkyl substituted with at least one non-hydrogen substituent selected from the group consisting of unsubstituted C3-7 cycloalkyl, C5-12 aryl, C5-12 heteroaryl and C1-4 alkoxycarbonyl; unsubstituted C3-7 cycloalkyl; C5-12 aryl; and C5-12 heteroaryl,
R2 and R3 are hydrogen; unsubstituted C1-7 alkyl; C5-12 aryl; or C5-12 heteroaryl, and
the aryl and heteroaryl are unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, hydroxyl and halogen.
4. The compound of Formula 1 or a pharmaceutically acceptable salt thereof of claim 3, wherein R1 and R4 are independently non-hydrogen substituents selected from the group consisting of unsubstituted C1-7 alkyl; C1-4 alkyl substituted with at least one non-hydrogen substituent selected from the group consisting of unsubstituted C3-7 cycloalkyl, C5-12 aryl, C5-12 heteroaryl and C1-4 alkoxycarbonyl; unsubstituted C3-7 cycloalkyl; C5-12 aryl; and C5-12 heteroaryl,
R2 and R3 are hydrogen; unsubstituted C1-7 alkyl; C5-12 aryl; or C5-12 heteroaryl, and
the aryl and heteroaryl may be unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C1-4 alkoxy, hydroxyl and halogen, and the aryl and heteroaryl may be selected from the group consisting of phenyl, pyridinyl, furanyl and isoquinolinyl.
5. The compound of Formula 1 or a pharmaceutically acceptable salt thereof of claim 4, wherein R1 is unsubstituted C1-7 alkyl; C1-4 alkyl substituted with C5-12 aryl or C5-12 heteroaryl; C5-12 aryl; or C5-12 heteroaryl,
R2 is hydrogen; or unsubstituted C1-7 alkyl,
R3 is hydrogen; unsubstituted C1-7 alkyl; C5-12 aryl; or C5-12 heteroaryl,
R4 is a non-hydrogen substituent selected from the group consisting of unsubstituted C1-7 alkyl; C1-4 alkyl substituted with at least one non-hydrogen substituent selected from the group consisting of unsubstituted C3-7 cycloalkyl, C5-12 aryl, C5-12 heteroaryl and C1-4 alkoxycarbonyl; unsubstituted C3-7 cycloalkyl; C5-12 aryl; and C5-12 heteroaryl, and
the aryl and heteroaryl may be unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C1-4 alkoxy, hydroxyl and halogen, and the aryl and heteroaryl may be selected from the group consisting of phenyl, pyridinyl, furanyl and isoquinolinyl.
6. The compound of Formula 1 or a pharmaceutically acceptable salt thereof of claim 1, wherein the compound of Formula 1 is N1-hexyl-N5-propyl biguanide; N1-hexyl-N5-cyclopropylmethyl biguanide; N1-hexyl-N5-cyclohexylmethyl biguanide; N1-hexyl-N5-benzyl biguanide; N1,N5-bis(4-chlorophenyl) biguanide; N1,N5-bis(3-chlorophenyl)biguanide; N1-(4-chloro)phenyl-N5-(4-methoxy)phenyl biguanide; N1,N5-bis(3-chloro-4-methoxyphenyl)biguanide; N1,N5-bis(3,4-dichlorophenyl) biguanide; N1,N5-bis(3,5-dichlorophenyl)biguanide; N1,N5-bis(4-bromophenyl)biguanide; N1-benzyl-N5-(pyridine-3-yl)methyl biguanide; N1-(phenethyl)-N5-propyl biguanide; N1-(phenethyl)-N5-cyclopropylmethyl biguanide; N1-(phenethyl)-N5-cycloheptyl biguanide; N1,N5-bis(phenethyl)biguanide; N1,N1,N5-trimethyl biguanide; N1,N1-dimethyl-N5-butyl biguanide; N1,N1-dimethyl-N5-(butan-2-yl)biguanide; N1,N1-dimethyl-N5-t-butyl biguanide; N1,N1-dimethyl-N5-pentyl biguanide; N1,N1-dimethyl-N5-methoxycarbonylethyl biguanide; N1,N1-dimethyl-N5-cycloheptyl biguanide; N1,N1-dimethyl-N5-cyclopropylmethyl biguanide; N1,N1-dimethyl-N5-(4-bromo)phenyl biguanide; N1,N1-dimethyl-N5-(furan-2-yl)methyl biguanide; N1,N1-dimethyl-N5-(pyridine-3-yl)methyl biguanide; N1,N1-dimethyl-N5-benzyl biguanide; N1,N1-dimethyl-N5-(phenethyl)biguanide; N1,N1-diethyl-N5-(3-chloro)phenyl biguanide; N1,N1-dipropyl-N5-(3-chloro)phenyl biguanide; N1,N1-(ethyl)(propyl)-N5-(4-chloro)phenyl biguanide; N1,N1-dipropyl-N5-(isoquionline-5-yl)biguanide; N1,N1-dihexyl-N5-(3-chloro)phenyl biguanide; N1,N1,N5,N5-tetraethyl biguanide; N1,N1-diethyl-N5,N5-(cyclohexyl)(methyl)biguanide; N1,N1-dipropyl-N5,N5-diethyl biguanide; N1,N1-dipropyl-N5,N5-(methyl)(phenethyl)biguanide; N1,N1-dipropyl-N5,N5-(4-hydroxylphenyl)(phenyl) biguanide; or N1,N1,N5,N5-bis((benzyl)(methyl))biguanide.
7. The compound of Formula 1 or a pharmaceutically acceptable salt thereof of claim 1, wherein the pharmaceutically acceptable salt is a salt with an acid selected from the group consisting of formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutylc acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranyl acid, benzensulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, dichloroacetic acid, aminooxy acetic acid, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid and boric acid.
8. A method of preparing a compound of Formula 1, comprising:
reacting a compound of Formula 2 with dicyanoamide in at least one organic solvent to obtain a compound of Formula 3; and
reacting the compound of Formula 3 with a compound of Formula 4 in at least one organic solvent to obtain the compound of Formula 1:
Wherein R1, R2, R3 and R4 are independently hydrogen or a non-hydrogen substituent selected from the group consisting of C1-12 alkyl unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C3-10 cycloalkyl, C5-12 aryl, C5-12 heteroaryl, hydroxyl, halogen and C1-4 alkoxycarbonyl; C3-10 cycloalkyl; C1-12 alkoxy; C5-12 aryl; C5-12 heteroaryl; hydroxyl; and halogen, and
the aryl and heteroaryl are unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, hydroxyl and halogen.
9. A drug comprising a compound of Formula 1 or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.
10.-16. (canceled)
17. A method of treating a disease, comprising:
administering a therapeutically effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt thereof according to claim 1 to a subject in need thereof, wherein the disease is selected from the group consisting of diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, muscle pain, myocyte damage and rhabdomyolysis.
18. The method of claim 17, wherein diabetes mellitus is insulin independent mellitus.
19. The method of claim 17, wherein the cancer is breast cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, blood cancer, prostate cancer, brain cancer, pancreatic cancer, ovarian cancer, or endometrial cancer.